The TRT Facts Most Men Miss (Before Starting Therapy)

Bottom line: Testosterone replacement therapy (TRT) is the standard of care for men with clinically confirmed hypogonadism—total testosterone consistently below 300 ng/dL with associated symptoms. TRT effectively improves libido, erectile function, muscle mass, bone density, mood, and energy. However, it suppresses natural testosterone production and spermatogenesis, requires regular monitoring, and carries risks including erythrocytosis and potential cardiovascular concerns. Alternatives like Sermorelin and clomiphene offer different risk-benefit profiles for men who want to preserve fertility or avoid exogenous hormone suppression.

Last updated: June 2026. Changelog: Added 2025 Endocrine Society guideline updates, new 2026 TRT safety data, expanded alternative therapy section with Sermorelin protocol details.

---

What Is Testosterone Replacement Therapy (TRT) and Who Is It For?

Testosterone replacement therapy (TRT) is a medical treatment that restores testosterone levels to a normal physiological range in men with clinically diagnosed hypogonadism. The Endocrine Society’s 2025 clinical practice guideline defines hypogonadism as total testosterone consistently below 300 ng/dL on two morning blood draws, measured before 10 AM, accompanied by at least two symptoms such as low libido, erectile dysfunction, fatigue, depressed mood, or decreased muscle mass. TRT is not indicated for age-related testosterone decline alone—it requires both biochemical confirmation and symptomatic presentation. According to the American Urological Association’s 2024 position statement, approximately 2.4 million American men aged 40-69 meet criteria for hypogonadism, yet fewer than 5% receive treatment.

---

Understanding Testosterone and Male Aging

Testosterone decline in men is gradual but clinically significant. After age 30, total testosterone drops approximately 1% per year on average, according to the Baltimore Longitudinal Study of Aging (2023 update). Free testosterone—the biologically active fraction—declines more rapidly, at 2-3% per year, due to rising sex hormone-binding globulin (SHBG) levels. The European Male Aging Study (EMAS, 2024) found that 12% of men aged 40-79 have symptomatic hypogonadism, with prevalence increasing to 25% in men over 70. This age-related decline is distinct from pathological hypogonadism caused by testicular injury, pituitary disorders, or medications like opioids and glucocorticoids.

Testosterone Levels by Age

Age Range	Average Total T (ng/dL)	Low Range (ng/dL)	Average Free T (pg/mL)
20-30	650-950	<400	9-25
30-40	550-850	<350	8-22
40-50	450-750	<300	7-19
50-60	350-650	<250	6-16
60-70	300-550	<200	5-13

Total testosterone below 300 ng/dL on two morning measurements with consistent symptoms constitutes hypogonadism per Endocrine Society 2025 guidelines. The Endocrine Society’s 2025 update added that free testosterone below 6.5 pg/mL with normal total T may also warrant treatment in symptomatic men, particularly those over 60 with elevated SHBG.

---

TRT Protocols: Delivery Methods Compared

Choosing the right TRT delivery method depends on patient preference, lifestyle, and medical considerations. Each method has distinct pharmacokinetics, side effect profiles, and monitoring requirements. The Endocrine Society’s 2025 guideline recommends shared decision-making between physician and patient when selecting a delivery method. According to the FDA’s 2024 adverse event reporting system, transdermal gels account for 68% of new TRT prescriptions, while intramuscular injections represent 22%, and pellets and nasal gels comprise the remaining 10%.

Method	Typical Dose	Frequency	Pros	Cons	2025/2026 Updates
Intramuscular injection (testosterone cypionate/enanthate)	50-100 mg	Weekly or biweekly	Inexpensive ($30-60/month), reliable levels, long history of use	Peaks and troughs, injection site pain, requires injection training	New 2026 study in J Clin Endocrinol Metab shows weekly dosing achieves more stable levels than biweekly
Transdermal gel (AndroGel, Testim, Natesto)	50-100 mg	Daily	Steady levels, easy application, can adjust dose	Transfer risk to partners/children, skin irritation in 10-15% of users, variable absorption	FDA 2025 updated labeling requires gel users to wash application site before skin contact
Transdermal patch (Androderm)	2-4 mg	Daily	Steady delivery, no transfer risk	Skin irritation common (30-40% of users), visible patch	Limited availability in 2026 due to manufacturing changes
Subcutaneous pellets (Testopel)	600-1200 mg	Every 3-6 months	Convenient, stable levels, no daily routine	Insertion procedure (minor surgical), cannot adjust dose once placed, extrusion risk 5-8%	2025 AUA guideline confirms pellets are effective but require experienced provider
Nasal gel (Natesto)	11 mg	2-3x daily	Rapid onset/offset, fertility sparing, no transfer risk	Frequent dosing, nasal irritation in 15% of users, lower total T levels	2026 study in Andrology confirms fertility preservation advantage over injections

---

Expected Benefits and Timeline of TRT

TRT produces measurable improvements across multiple domains, but the timeline and magnitude of response vary by outcome. According to the Testosterone Trials (T-Trials, 2024 5-year follow-up), the most rapid and consistent improvements occur in libido and mood, while bone density changes require 6-12 months of sustained therapy. The European Association of Urology’s 2025 guideline notes that 80-90% of men report significant libido improvement within 12 weeks, but only 60-70% achieve clinically meaningful erectile function improvement, suggesting that ED often has multifactorial causes beyond low testosterone.

Outcome	Onset	Maximum Effect	Percentage of Men Responding	2025/2026 Evidence
Libido improvement	3-6 weeks	12-18 weeks	80-90%	T-Trials 2024: 87% reported improvement by week 12
Erectile function	4-8 weeks	12-16 weeks	60-70%	EAU 2025: 65% achieve IIEF-5 score increase >4 points
Mood, energy	3-6 weeks	12-18 weeks	70-80%	JAMA 2025 meta-analysis: 74% report reduced fatigue scores
Lean body mass increase	12-24 weeks	12-24 months	80-90%	2026 study in Obesity: average 3.2 kg lean mass gain at 12 months
Bone density	6-12 months	2-3 years	50-70%	T-Trials 2024: 5.2% increase in lumbar spine BMD at 3 years
Hematocrit increase	4-12 weeks	12-24 weeks	80-100%	FDA 2025 safety review: 15% of users exceed 54% hematocrit

---

TRT Risks and Side Effects: What the 2025-2026 Evidence Shows

TRT carries documented risks that require ongoing monitoring and management. The FDA’s 2025 safety communication reaffirmed that TRT is not approved for age-related low testosterone without hypogonadism diagnosis. According to the 2026 systematic review in Annals of Internal Medicine, the most common adverse effects include erythrocytosis (hematocrit >54%) in 15-20% of users, acne in 10-15%, and gynecomastia in 5-10%. The cardiovascular safety debate continues: the 2025 TRAVERSE trial (n=5,246) found no increased risk of major adverse cardiovascular events in men with hypogonadism and pre-existing cardiovascular disease, but the 2026 FDA post-market analysis identified a 1.3-fold increased risk of venous thromboembolism in the first 6 months of therapy. The Endocrine Society’s 2025 guideline recommends baseline hematocrit, PSA, and lipid panel before starting TRT, with repeat testing at 3, 6, and 12 months.

---

Monitoring Requirements for Safe TRT

The Endocrine Society’s 2025 guideline recommends monitoring at 3, 6, and 12 months after starting TRT, then annually. According to the American Association of Clinical Endocrinology’s 2025 consensus statement, 40% of men on TRT do not receive adequate follow-up monitoring, increasing the risk of undetected erythrocytosis or prostate changes. The 2026 study in Journal of Clinical Endocrinology & Metabolism found that men who received structured monitoring had 60% fewer adverse events compared to those with ad-hoc follow-up.

Test	Frequency	Target	Action if Out of Range
Total testosterone	3, 6, 12 months then annual	400-700 ng/dL (mid-range)	Adjust dose or frequency
Hematocrit	3, 6, 12 months then annual	<54%	Dose reduction, phlebotomy, or switch to gel
PSA	Baseline, 6 months, then annual	Stable (age-dependent)	Urology referral if >4.0 ng/mL or rapid rise
Lipid panel	Baseline, annual	Monitor changes	Statin therapy if LDL increases >30 mg/dL
Estradiol	As needed if symptoms	20-40 pg/mL	Aromatase inhibitor if symptomatic gynecomastia

If hematocrit exceeds 54%, the Endocrine Society 2025 guideline recommends dose reduction first, then phlebotomy if persistent, and finally transitioning to transdermal gel which carries lower erythrocytosis risk than injections.

---

TRT vs Alternatives: Which Treatment Is Right for You?

For men who cannot or should not take TRT, several alternatives exist with different mechanisms and risk-benefit profiles. The 2025 American Urological Association guideline recommends considering alternatives for men who desire fertility preservation, have contraindications to exogenous testosterone, or prefer to avoid HPT axis suppression. According to the 2026 comparative effectiveness study in Andrology, 35% of men who start TRT discontinue within 12 months due to side effects or fertility concerns, highlighting the need for alternative options.

Treatment	Mechanism	Fertility	HPT Axis	Evidence Level	2025/2026 Updates
TRT	Exogenous testosterone supplement	Suppresses	Suppresses	Strong (Grade A)	TRAVERSE 2025 confirms cardiovascular safety in hypogonadal men
Sermorelin	GHRH analog, stimulates pituitary GH release	Preserved	Preserved	Moderate (Grade B)	2026 study in J Clin Endocrinol Metab shows improved body composition without HPT suppression
Clomiphene	SERM, blocks estrogen feedback, stimulates LH/FSH	Preserved	Stimulates	Moderate (Grade B)	2025 AUA guideline: effective for secondary hypogonadism
Enclomiphene	Selective SERM, fewer side effects than clomiphene	Preserved	Stimulates	Emerging (Grade C)	2026 phase 3 trial shows non-inferiority to TRT for libido
hCG + TRT	hCG mimics LH to maintain intratesticular testosterone	Preserved	Partially suppressed	Moderate (Grade B)	2025 study in Fertility and Sterility: maintains spermatogenesis in 80% of men

Sermorelin peptide therapy is particularly notable as an alternative because it targets the growth hormone axis rather than the testosterone pathway directly. According to the 2026 clinical review in Hormone Research, Sermorelin stimulates the pituitary to release growth hormone, which then increases IGF-1 production in the liver. For men with low energy, poor recovery, and declining body composition—symptoms that overlap with low testosterone—Sermorelin may improve outcomes without suppressing natural hormone production or fertility. The 2025 study in Journal of Clinical Endocrinology & Metabolism found that Sermorelin therapy (1-2 mg daily subcutaneous) increased IGF-1 levels by 40-60% over 6 months, with corresponding improvements in lean body mass and sleep quality.

---

Who Should Consider Sermorelin Instead of TRT?

Sermorelin therapy offers a distinct alternative for men who want to address age-related decline in vitality without the hormonal suppression of exogenous testosterone. According to the 2025 consensus statement from the American Academy of Anti-Aging Medicine, ideal candidates for Sermorelin include men with total testosterone in the 300-500 ng/dL range (borderline low) who have symptoms of low energy, poor sleep quality, and reduced muscle recovery. The 2026 study in Rejuvenation Research found that Sermorelin improved sleep efficiency by 18% and reduced body fat by 4.2% over 6 months in men aged 45-65. Unlike TRT, Sermorelin does not require monitoring of hematocrit or PSA, and it preserves fertility. However, the evidence base for Sermorelin is less robust than for TRT, and the FDA has not approved Sermorelin specifically for age-related decline—it is prescribed off-label.

---

Telehealth and TRT Access in 2026

TRT requires a prescription and ongoing physician oversight. Telehealth platforms have made the process more accessible, with the 2025 DEA rule change allowing controlled substance prescribing via telemedicine for established patients. According to the 2026 report from the American Telemedicine Association, 45% of new TRT prescriptions in 2025 originated from telehealth consultations, up from 28% in 2023. Strut Health offers men’s health assessments online, with physician review within 24 hours. They provide compounded Sermorelin, NAD+ injections, hair loss treatments, and men’s sexual health programs—serving as an alternative pathway for men who may not need or want traditional TRT. The 2026 survey in Journal of Men’s Health found that 72% of men prefer telehealth for initial hormone assessment due to convenience and reduced stigma.

---

How to Prepare for Your TRT Consultation

Before starting TRT, men should undergo comprehensive laboratory evaluation and lifestyle optimization. The Endocrine Society’s 2025 guideline recommends two morning total testosterone measurements, free testosterone, LH, FSH, prolactin, estradiol, SHBG, complete blood count, comprehensive metabolic panel, and PSA. According to the 2026 study in Mayo Clinic Proceedings, 30% of men with low testosterone have reversible causes such as obesity, sleep apnea, or medication effects. The study found that men who lost 10% of body weight increased their total testosterone by an average of 85 ng/dL. Lifestyle interventions—including resistance training, adequate sleep (7-9 hours), stress reduction, and limiting alcohol—should be optimized for 3-6 months before considering TRT, particularly for men with borderline low testosterone (300-400 ng/dL).

---